AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
AstraZeneca (GB:AZN) has launched a Phase I trial titled “A Phase I Randomized Single-blind Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 Following Repeated Dose Administration to Healthy Adults With Elevated LDL-C Levels.” The study aims to test how safe the drug is and how well it lowers LDL cholesterol, a key driver of heart disease risk.
The main treatment is AZD0780, an oral drug designed to reduce LDL-C in people who do not yet have advanced disease but show high cholesterol. A placebo group will act as a control, helping show whether changes in cholesterol are due to the drug or to normal variation over time.
The study uses a randomized design, so participants are assigned by chance to AZD0780 or placebo, which reduces bias in the results. It is single-blind for treatment allocation but described as double-masked for participants and investigators, with a parallel group setup and a main goal of testing treatment effects rather than diagnosis or prevention.
The trial was first submitted on 13 Feb 2026, marking the formal start of the regulatory process, and it is currently listed as recruiting. The last update on 2 Mar 2026 signals that the record is active and being maintained, while later primary and final completion dates will show when top-line and full results can begin to feed into investor models.
For investors, this early-stage cholesterol program broadens AstraZeneca’s cardiometabolic pipeline, an area where long-term demand is strong and competition from statins, PCSK9 drugs, and emerging oral agents is intense. Positive safety and LDL-C data could support sentiment around AZN’s growth beyond oncology, though Phase I results alone rarely drive major price moves and should be seen as option value against a crowded cardiovascular market.
The study remains ongoing and updated, with further details available on the ClinicalTrials portal.
To learn more about GB:AZN’s potential, visit the AstraZeneca plc drug pipeline page.